Navigation Links
Mount Everest to be Site of Research into Hypoxia

The Xtreme-Everest Team has announced at the Cheltenham Science Festival that it plans to send a 20 member expedition team to mount Everest to conduct //a research into the effects of low oxygen levels, hypoxia

Doctors and scientists from the Centre for Aviation, Space and Extreme Environment Medicine at the Institute of Human Health and Performance, University College London will be conducting the research along with researchers around the world. The aim of the study is to increase survival levels for intensive care patients

Dr Hugh Montgomery, the leader of the expedition said: ‘At the 8,850-metre summit of Everest, there's so little oxygen getting into the lungs that the body quickly starts shutting down and mountaineers risk slipping into a coma. These extreme conditions mimic what it's like for patients in intensive care and studying the human body in this environment will teach us invaluable lessons in the science of survival.’

According to Dr Mike Grocott said: ‘One in six Britons will spend time in an intensive care unit and, shocking as it may sound, up to three in 10 do not pull through. We know that mountaineers survive on low oxygen levels that would take the lives of intensive care patients in minutes.

‘Our ascent will involve creating the world's highest medical laboratory, taking field science to a new level.’

He also said that Everest's summit was at exactly the limit of human tolerance for hypoxia and for many years doctors and scientists had believed that it would be impossible to reach it without supplemental oxygen. Today mountaineers like Reinhold Messner have proved otherwise. Should the mountain have been even a few meters higher the dream of scaling Mount Everest would never have become a reality.

Dr Montgomery had earlier identified a gene that controls improved performance at high altitude. He claims that the summit of Everest is a wonderful natural laboratory for the
'"/>




Page: 1 2

Related medicine news :

1. Mountain biking connected to infertility
2. Spread Of Rocky Mountain Spotted Fever Is A Probability, Say Experts
3. Epidemic Fear In Mumbai Mounting Post-Floods
4. Non-Communicable Diseases Mounting Up At An Alarming Rate in India
5. Illegal Drug Use In England Mounting Up At An Alarming Rate
6. Indonesia Has Ninth Bird-Flu Death as Risk Mounts
7. Mountain Biking Results In Serious Injuries
8. CNIC To Provide Funds To Mount Sinai School
9. Antioxidants Could Halt Rocky Mountain Spotted Fever
10. Lab On Mount Everest A Reality Next March
11. Ignorance - the main reason behind deaths on Mount Everest
Post Your Comments:
(Date:8/29/2008)...ton Scientific obligation reduced from $250 to $19...tCall/ -- Boston Scientific,Corporation (NYSE: BS...f,Marshall, Texas found two patents of Medtronic, ...onduct during the prosecution of the patents,befor... A jury had previously found that certain Boston S...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal C...rn California to provide protection for cash payin... the Hispanic community is benefiting. , ... 2008 -- Dr. Milton Owens and the Coastal Center f...fornia to provide protection for cash paying patie...
(Date:8/29/2008)... Trusted life science software prov...lients to engage via GSA. , ...ions, an emerging software engineering firm dedic...a U.S. General Services Administration (GSA) Contr...stomers with the ability to conveniently engage 5A...
(Date:8/28/2008)...enues increase 138% versus Q2 2007 - Nine new C.../PRNewswire-FirstCall/ - CRH Medical Corporation,(...he three and six months,ended June 30, 2008 (all f...onths ended June 30, 2008 increased 138% to $1,653...007. Revenue for the six months ended June,30, 200...
Breaking Medicine News(10 mins):Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5
...h regulators, gave their nod to the first new drug...heart transplant patients.// The drug, Astellas Ph... rejection of liver and kidney transplants. Dr. S... Center for Drug Evaluation and Research said, "Th...
...dia’s population stabilization solely rests on the... which has the highest fertility rates. 'India's p...ttar Pradesh take an immediate lead in checking po...ecutive director, Population Foundation of India, ...
...rther six months of patent extension by the FDA fo...n//, Provigil. Cephlaon had complied with the te...he provision of clinical studies data after studyi...on pediatric patients. Cephalon has settled the ‘...
...ncreased risk of heart attack associated with Viox...views are 'out of the mainstream' as it is based o...Merck and Co. Thomas Cona and John Mcdarby have s...g that use of the drug had resulted in heart attac...
Other Medicine News:Health News:Doctor Grilled In Court For False Report About Vioxx Health Risk 2
(Date:8/27/2008)...prednisone arm demonstrated a, significant surviv...se -, CAMBRIDGE, Mass., Aug. 27 /- M...nced the publication of results from the 682,patie...eek,s edition of the,New England Journal of Medici...fit and a 30 percent complete remission (CR) rate ...
(Date:8/27/2008)...al, expected by mid-2009 - - Data from second Pha...CKVILLE, Md., Aug. 27 /- Hu...nnounced it has completed enrollment,and initial d... 3,randomized clinical trials of LymphoStat-B(R) (...erythematosus (SLE). Belimumab is being developed ...
(Date:8/26/2008)...mafore Pharmaceuticals Inc.,presented data at the ...es,in Cancer in Washington, D.C., announcing the d... that demonstrate significant anticancer,activity ...molecular scaffold has been developed using,comput...3 kinase inhibitors,as well as isoform-selective s...
(Date:8/26/2008)...FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today a...,from the CUSTOM II trial was published in the mos...ntervention. The lead author of the article was,Dr...nter Utrecht, Utrecht,The Netherlands on behalf o...es across Europe., The one-year CUSTOM II trial, ...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Older Americans are more socially engaged than many people may think 16988 1Older Americans are more socially engaged than many people may think 16988 2Older Americans are more socially engaged than many people may think 16988 3Is there anybody out there 3F 2916 1Is there anybody out there 3F 2916 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 155 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 3MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 1MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 2
...of Peregrine,s,Unique Selective Anti-VEGF Antibodi...l Cancer Models, TUSTIN, Calif., April 20, 2007 /P... Inc. , a clinical stage,biopharmaceutical company... treatment of cancer and hepatitis C virus infecti... presented at the recent,Centennial Annual Meeting...
...Rx Corporation,(NASDAQ:CYTR) today announced that ...clusively licensed to its majority-owned,subsidiar...,published in the April 2007 issue of peer-reviewe...hnology was developed by RXi,Co-founder, Scientifi...setts Medical School (UMMS) Professor of Biochemis...
Other Medicine Technology:Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: